MoSHe platform compounds
Preclinical
AmgenMoSHe platform compounds is one of 6 therapeutic programs targeting Muscular Dystrophy. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
6 competitors in Muscular Dystrophy
#DrugCompanyPhaseTrials
1Cialis
Eli LillyApproved
Glucophage
EMD SeronoApproved
Duvyzat
ItalfarmacoPhase 3
Glucocorticoid
AbbViePhase 3
HB-Admscs
HHope Biosciences Research Foundation
Preclinical
MoSHe platform compounds
AmgenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for MoSHe platform compounds. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company